After revoking Sarepta’s award in July and awarding one to Krystal last month, the FDA’s platform technology designation ...

Moderna is currently in the middle of an aggressive cost-cutting campaign. In September last year, the company announced that ...

The regulator has received reports that a group of patients treated with Adzynma had neutralizing antibodies against the ...

The nod brings Bayer face-to-face in the market with Boehringer Ingelheim and AstraZeneca, each of which has its own HER2 ...

AnaptysBio has separately alleged that GSK subsidiary Tesaro breached “certain requirements” under their 2014 license agreement involving a program that would become GSK's Jemperli.

While expressing disappointment, William Blair analysts were unsurprised by the Phase II failure, having assigned the VISTA study a high level of risk given the “mixed” performance of a similar drug ...

Aspen is now also considering the possibility of an initial public offering next year in an effort to bring its cell therapy ...

Eli Lilly has broken free from the Big Pharma pack. Fueled by sky-high expectations for the GLP-1 market, Lilly has achieved ...

Biopharma professionals will probably find decreasing employment opportunities this month and next even as layoffs continue, ...

A new analysis from Jefferies shows that drugs receiving breakthrough designations sail through the regulatory process more ...

Lundbeck had tried to scoop the narcolepsy drug maker out from under Alkeremes with $2.4 billion, but Avadel has elected to ...

If Eli Lilly's obesity pill orforglipron is approved and priced around $200 per month, analysts at Truist predict patients ...